文献速递胸部肿瘤放疗

全州联盟中接受术后放疗的肺癌患者心脏与肺剂量学参数

Cardiac and Pulmonary Dosimetric Parameters in Patients With Lung Cancer Undergoing Postoperative Radiation Therapy Across a Statewide Consortium.
PubMed 文献 · Pract Radiat Oncol · 2023-02-06

该研究基于密歇根放射肿瘤质量联盟2012至2022年前瞻性收集的377例非转移性非小细胞肺癌术后放疗患者数据,分析心脏和肺剂量暴露。结果显示IMRT使用率66%,心脏平均剂量中位数8.7 Gy,肺平均剂量中位数11.4 Gy,这些参数略低于Lung ART报告值,且不因治疗方式或切缘状态显著差异。

要点

  • 66%患者接受IMRT,32%接受3D-CRT,3D-CRT组计划靶区体积显著更小(149.2 vs 265.4 cm³,P < .0001)。
  • 全组心脏平均剂量中位数8.7 Gy(IQR 3.5-15.3 Gy),肺平均剂量中位数11.4 Gy(IQR 8.1-14.3 Gy)。
  • 心脏和肺剂量学参数在IMRT与3D-CRT之间、切缘阳性与阴性之间均无显著差异。

核心结论

  • 随着IMRT使用率增加,该全州联盟中心脏和肺剂量学参数略低于Lung ART报告值。
  • 这些数据为切缘阳性患者术后放疗的计划设计提供了有用的基准。

研究设计与样本

  • 前瞻性收集2012年至2022年密歇根放射肿瘤质量联盟内27个学术和社区中心377例接受术后放疗的非转移性非小细胞肺癌患者的人口学和剂量学数据。
  • 从剂量体积直方图计算靶区覆盖和危及器官暴露的剂量学参数,并评估3D-CRT和IMRT的使用率。

主要发现

  • 51%患者手术时为N2期,25%切缘阳性;66%接受IMRT,32%接受3D-CRT。
  • 3D-CRT组计划靶区体积显著小于IMRT组(149.2 vs 265.4 cm³;P < .0001)。
  • 全组心脏平均剂量中位数8.7 Gy(IQR 3.5-15.3 Gy),心脏V5中位数35.2%(IQR 18.5%-60.2%),心脏V35中位数9%(IQR 3.2%-17.7%)。
  • 全组肺平均剂量中位数11.4 Gy(IQR 8.1-14.3 Gy),肺V20中位数19.6%(IQR 12.7%-25.4%)。
  • 上述剂量学参数在IMRT与3D-CRT之间、切缘阳性与阴性患者之间均无显著差异。

临床怎么用

  • 原文指出这些数据为切缘阳性患者术后放疗的计划设计提供了有用的基准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The recently published Lung Adjuvant Radiotherapy Trial (Lung ART) reported increased rates of cardiac and pulmonary toxic effects in the postoperative radiation therapy (PORT) arm. It remains unknown whether the dosimetric parameters reported in Lung ART are representative of contemporary real-world practice, which remains relevant for patients undergoing PORT for positive surgical margins. The purpose of this study was to examine heart and lung dose exposure in patients receiving PORT for non-small cell lung cancer across a statewide consortium. METHODS AND MATERIALS: From 2012 to 2022, demographic and dosimetric data were prospectively collected for 377 patients at 27 academic and community centers within the Michigan Radiation Oncology Quality Consortium undergoing PORT for nonmetastatic non-small cell lung cancer. Dosimetric parameters for target coverage and organ-at-risk exposure were calculated using data from dose-volume histograms, and rates of 3-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) utilization were assessed. RESULTS: Fifty-one percent of patients in this cohort had N2 disease at the time of surgery, and 25% had a positive margin. Sixty-six percent of patients were treated with IMRT compared with 32% with 3D-CRT. The planning target volume was significantly smaller in patients treated with 3D-CRT (149.2 vs 265.4 cm3; P < .0001). The median mean heart dose for all patients was 8.7 Gy (interquartile range [IQR], 3.5-15.3 Gy), the median heart volume receiving at least 5 Gy (V5) was 35.2% (IQR, 18.5%-60.2%), and the median heart volume receiving at least 35 Gy (V35) was 9% (IQR, 3.2%-17.7%). The median mean lung dose was 11.4 Gy (IQR, 8.1-14.3 Gy), and the median lung volume receiving at least 20 Gy (V20) was 19.6% (IQR, 12.7%-25.4%). These dosimetric parameters did not significantly differ by treatment modality (IMRT vs 3D-CRT) or in patients with positive versus negative surgical margins. CONCLUSIONS: With increased rates of IMRT use, cardiac and lung dosimetric parameters in this statewide consortium were slightly lower than those reported in Lung ART. These data provide useful benchmarks for treatment planning in patients undergoing PORT for positive surgical margins.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Herr DJ, Yin H, Allen SG, et al. Cardiac and Pulmonary Dosimetric Parameters in Patients With Lung Cancer Undergoing Postoperative Radiation Therapy Across a Statewide Consortium. Pract Radiat Oncol. 2023. PMID: 36754278. doi:10.1016/j.prro.2023.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。